REPORT OF THE NATIONAL CANCER REGISTRY

Dec, 2025

CANCER IN THE REPUBLIC OF MAURITIUS

INCIDENCE AND MORTALITY STUDY FOR 2024

MINISTRY OF HEALTH AND WELLNESS

AFRICAN CANCER REGISTRY NETWORK

WORLD HEALTH ORGANIZATION

FOREWORD

I am pleased to present the 2024 report of the Mauritius National Cancer Registry (MNCR), which provides the latest data on cancer incidence and mortality in the Republic of Mauritius. This information remains central to planning prevention, screening, treatment, and supportive care services.

The 2024 figures show that cancer continues to pose a major health challenge, with prostate cancer leading among men and breast cancer among women. These trends follow global patterns and highlight the need for sustained efforts to improve early detection and ensure equitable access to quality care.

The MNCR maintains high standards in cancer surveillance through internationally recognised methods and ongoing collaboration with regional and global partners, including the African Cancer Registry Network. These partnerships support the production of reliable and transparent data.

This publication is also aligned with the World Cancer Day 2025–2027 campaign, “United by Unique”, which calls for people-centred, inclusive approaches to cancer control. These aims mirror our national priorities to reduce inequalities and strengthen services for those most affected.

I commend the MNCR team, led by Dr M. Koon Sun Pat, for their continued dedication, and acknowledge the cooperation of clinicians, laboratories, hospitals, and partners who contribute to this work. The insights in this report will guide our policies and programmes as we strive to reduce preventable cancers, improve survival, and protect the health of our population.

Hon. A.K. Bachoo, G.O.S.K
Minister of Health and Wellness

ACKNOWLEDGEMENTS

The Mauritius National Cancer Registry (MNCR) is grateful to local and international partners that supported the organisation during the period under review.

1. Hon A.K. Bachoo, G.O.S.K, Minister of Health and Wellness
2. Mr. P. Mawah, Ag. Senior Chief Executive
3. Dr A. Dinassing, Ag. Director General Health Services
4. Mrs A. Seenundun, Permanent Secretary
5. Dr. I.D.I Nawoor, Director Health Services
6. Mrs S. Kalasopatan-Chellen, Deputy Permanent Secretary
7. Dr Z. Nabee, Ag. Deputy Permanent Secretary
8. Mrs M. Nuckecheddy, Assistant Permanent Secretary
9. WHO Country Office, Port-Louis
10. African Cancer Registry Network (AFCRN)
11. International Association of Cancer Registries, IACR (Lyon)
12. International Agency for Research on Cancer, IARC (Lyon)

Our sincere thanks go to all units/departments who have assisted and contributed as sources of data for the registry namely:

1. National Cancer Centre (NCC)
2. Laboratory archives, CHL
3. Regional hospital Health Records Department
4. Statistics Unit, MOHW
5. Overseas Treatment Unit, MOHW
6. The Civil Status Office, Prime Minister's Office

We are grateful for the continued support of the National Cancer Registry Steering Committee members: -

National Cancer Registry Steering Committee

- Dr A. Dinassing, Ag. Director General Health Services, MOHW (Chairman)
- Dr. I.D.I Nawoor, Director Health Services
- Dr (Mrs) J. Sonoo, Director Laboratory Services
- Dr (Mrs) S. Prasad-Chooromoney, Consultant-in-Charge (Clinical), NCC
- Dr A. Chinniah, Consultant-in-Charge (Radiotherapy), NCC
- Dr M. Koon Sun Pat, National Cancer Registry Coordinator
- Mr G.R Lall Mahomed, Ag. Chief Health Records Officer
- Mrs T. Rozbully-Sowdagur, Ag. Chief Health Statistician

We express our gratitude to the staff of the National Cancer Registry Task Force for their coordination of activities, data collection and processing, as well as their contributions to the writing of the report:

National Cancer Registry Task Force

- Dr M. Koon Sun Pat, National Cancer Registry Coordinator
- Dr (Mrs) C. P. Leste Boodoo, General Practitioner
- Mrs S.D. Chumun, Health Care Assistant
- Mrs G. Battalee, Health Care Assistant

We are thankful to Dr S.S. Manraj and Mr S. Ramjaun former members of the National Cancer Registry for their legacy and trust in the new team.

As regards to the private sector, we are grateful to Wellkin Hospital, Twinmed Laboratory as well as the public and private pathologists for their collaboration in providing cancer data.

National Cancer Registry of Mauritius (2024)

1 EXECUTIVE SUMMARY

Incidence Data

During the year 2024, 3362 new cancer cases were diagnosed, 1471 were among males and 1891 among females. The main five cancer sites among males are as follows:

Site	Number	Percentage (%)	ASIR – World (per 100,000)
Prostate	251	18.5	23.7
Colorectal	209	15.4	21.3
Lung	137	10.1	13.3
Mouth and Pharynx	69	5.0	7.4
Bladder	68	5.0	6.6

Among females, the five main cancer sites are:

Site	Number	Percentage (%)	ASIR – World (per 100,000)
Breast	679	37.5	66.8
Corpus uteri	191	10.5	18.8
Colorectal	177	9.8	15.6
Ovary	108	6.0	11.0
Cervix uteri	85	4.7	9.5

The mean age for cancer incidence for males was 63.8 years and 59.8 years for females. Cancers among individuals aged 60 years and older accounted for 62.0% of all cases, with 70.1% occurring in males and 55.9% in females. Among those in their productive years (15 – 64 years), 44.4% of cancers were diagnosed in men and 57.3% in women. Paediatric cancers, affecting children aged 0–14 years, accounted for only 0.75% of all cases. Sex ratio (M/F) for cancer incidence was 0.76.

The total number of cancer cases has steadily increased over the years among both males and females, with the latter being more diagnosed with the disease than males. The overall Age Standardised Incidence Rate (ASIR) trend is increasing, particularly for prostate and colorectal cancers, while lung and stomach cancer rates have remained stable, and mouth and pharynx cancers have slightly decreased among males. Among females, breast cancer was the most common cancer, with a significant increase over time, followed by notable upward trends in colorectal, corpus uteri, and ovarian cancers. In contrast, cervical cancer rates decreased from 2001 to 2018 and have since stabilised.

Concerning the data quality indicators, there were no cases with unknown age recorded. Only 2.2% of cases had an unknown primary site. Regarding the basis of diagnosis, Microscopic Verification (MV) was performed for 85.7% of cases, and Clinical Investigations (CLIN) accounted for 14.3% of cases.

Mortality Data

In 2024, out of a total of 12,493 deaths in Mauritius, 1,649 were attributed to cancer, with 803 deaths occurring in males and 846 in females, resulting in a male-to-female mortality sex ratio of 0.95. Cancer is still the third cause of death after cardiovascular diseases and diabetes mellitus and its complications. The overall Mortality/Incidence (MI) ratio was 0.55 for males and 0.45 for females.

The main five cancer sites among males are as follows:

Site	Number	Percentage (%)	ASMR – World (per 100,000)
Lung	123	15.3	12.0
Prostate	111	13.8	10.7
Colorectal	102	12.7	10.2
Stomach	49	6.1	4.8
Pancreas	48	6.0	4.6

Among females, the five main cancer sites are:

Site	Number	Percentage (%)	ASMR – World (per 100,000)
Breast	244	28.8	21.2
Colorectal	96	11.3	7.2
Lung	60	7.1	4.9
Ovary	60	7.1	5.6
Corpus Uteri	56	6.6	4.9

The Age Standardised Mortality Rates (ASMR) display clear and contrasting trends. Mortality rates among males remain consistently higher than those among females but show a gradual overall decline, with a small increase in the most recent period. In contrast, female mortality rises steadily before easing slightly thereafter. These opposing patterns balance each other, resulting in a total mortality rate that remains largely stable, with only modest variation across the study period.

2 BACKGROUND AND POPULATION

2.1 BACKGROUND

Since its independence, Mauritius has undergone an epidemiological transition, marked by a shift in the pattern of diseases. The country moved from being dominated by infectious and vector-borne diseases, such as tuberculosis and malaria, to one characterized by a predominance of chronic and non-communicable diseases (NCDs), including cancer. This transition underscores the growing importance of cancer surveillance and the role of the Mauritius National Cancer Registry (MNCR) in addressing the increasing cancer burden.

The MNCR was established in 1993 under the leadership of Dr Shyam Manraj with support from French cooperation. Initially, the registry functioned as a pathology-based registry housed at the Central Health Laboratory, Victoria Hospital. It gained affiliation with the International Association of Cancer Registries (IACR) in 1997, and its first report, covering the period 1989–1996, was published in 1999.

The MNCR transitioned to a population-based registry in 2001. Data processing initially used CanReg software, with the CanReg5 version implemented in 2010 to enhance data management and analysis. Demonstrating the quality of its data, the MNCR's information was included in the 12th edition of the *Cancer Incidence in Five Continents* publication, a globally recognized series showcasing reliable and high-quality cancer registry data.

The registry has also contributed to the global cancer registration community by hosting the 33rd Annual Meeting of the IACR in 2011 at Balaclava. It became a member of the African Cancer Registry Network (AFCRN) in 2013, further strengthening its regional and international collaborations.

The primary objective of the MNCR is to systematically collect, analyse, and disseminate data on cancer incidence, mortality and trends in the Republic of Mauritius. This information is crucial for monitoring the cancer burden, informing public health strategies, guiding resource allocation, and evaluating the effectiveness of cancer prevention and control programs.

2.2 POPULATION

The Registry covers the entire population of the Republic of Mauritius including Rodrigues and the other outer islands.

The estimated average mid-year population was 1,245,449 (616,479 males and 628,970 females) in 2024 according to the Health Statistics Report 2024 of the Ministry of Health and Wellness.



Fig 1. Estimated average annual population for the year 2024



Fig 2. Geographical area covered: The Republic of Mauritius

3 METHODS

3.1 SOURCES OF DATA

Data for 2024 was collected retrospectively from multiple sources. The primary data sources included the radiotherapy patient register, regional hospital records, and laboratory archives at the Central Health Laboratory (CHL), Victoria Hospital, which were utilised to identify cancer cases. At the CHL, cancer cases were retrieved from the histopathology department (including histopathology and bone marrow biopsy reports), cytology department (cytology reports), biochemistry department (tumour markers), and immunochemistry department (immunochemistry reports). This data was further supplemented by information from the Overseas Treatment Unit (OTU), some private pathology services (Twinmed and C-Care Welkin) and the record department of C-Care Welkin.



Fig.3 Organigram of the sources of information where data is collected

3.2 METHODS OF DATA COLLECTION

Similar to the previous year, data collection was conducted passively. However, since July 2024, the MNCR has also adopted an active data collection approach, with staff directly abstracting information from medical records at the National Cancer Centre in Solferino.

3.3 DEATH CERTIFICATES

Similar to the previous year the MNCR received only anonymised data from the Civil Status Office for the period of the study. Consequently, we were not able to retrieve Death Certificate Only (DCO) cases. Once data containing names and National Identification Numbers (NID) becomes available, the MNCR will update the registry accordingly. During the reporting period, however, cancer-related deaths recorded at the five regional hospitals were received and incorporated into the registry. These hospital-based records provide an important interim source of mortality information and contribute to strengthening the completeness of the registry.

3.4 VARIABLE

The variables abstracted include the patient's administrative details, tumour-specific information and the sources of data. The mandatory variables are: surname, first name, sex, age, date of birth, address, incidence date, topography, morphology, behaviour, and basis of diagnosis.

Benign conditions—such as thyrotoxicosis, keloids, and adenomas—were excluded, with the exception of brain tumours and High-Grade Squamous Intraepithelial Lesions (HSIL) of the cervix. Cases involving foreign nationals were also excluded.

3.5 CLASSIFICATION AND CODING

Data was coded using the ICD-O 3rd edition and ICD-10 classifications, then analysed and stored in the CanReg5 software. When TNM staging was unavailable for certain sites, Essential TNM was utilised, particularly during active surveillance efforts.

3.6 THE DATABASE

The registry uses CanReg5 software (http://www.iacr.com.fr/CanReg5) for data entry, management and analysis.
The 'IARCcrgTOOL' software was run to check for any inconsistency on the data. Population estimates data available by sex and 5-year age groups have been utilised as denominators to calculate incidence.

3.7 CONFIDENTIALITY

The registry adheres to the guidelines of the IACR/IARC (2004) with respect to the preservation of confidentiality in connection with or during the process of collection, storage, use and transmission of identifiable data. Requests for the release of data should be made in writing to the registry; requests for data involving identification of individual subjects require special permission, involving appropriate safeguards for confidentiality.

3.8 STATISTICAL METHODS

3.8.1 Age-specific rate

The age-specific rate is calculated simply by dividing the number of cancer deaths observed in a given age category during a given time period by the corresponding number of person years in the population at risk in the same age category and time period.

For cancer, the result is usually expressed as an annual rate per 100,000 person-years.

3.8.2 Crude incidence rate

The crude incidence rate is the number of new cases of cancer diagnosed in a specified population during a given time period, divided by the total size of that population, and is often expressed per 100,000 people. It reflects the actual burden of disease in the population, making it useful for resource planning and public health management. However, it is influenced by the age structure of the population, which can limit its use for comparisons between populations with different demographic profiles.

3.8.3 Age-standardisation rate

An age-standardised rate (ASR) is a summary measure of the rate that a population would have if it had a standard age structure.

Standardization is necessary when comparing several populations that differ with respect to age because age has a powerful influence on the risk of dying from cancer.

The ASR is a weighted mean of the age-specific rates; the weights are taken from population distribution of the standard population.

The ASR is also expressed per 100,000.

3.8.4 Cumulative risk

Cumulative mortality is the probability or risk of individuals dying from the disease during a specified period.

For cancer, it is expressed as the number of new born children (out of 100, or 1000) who would be expected to die from a particular cancer before the age of 75 or (65 or 70) if they had the rates of cancer observed in the period in the absence of competing causes.

Like the age standardised rate, it permits comparisons between populations of different age structures.

4 RESULTS

In 2024, the cancer registry registered 3362 cases of cancers: 1471 among men and 1891 among women.

4.1 NUMBER OF CASES IN PERIOD, BY AGE GROUP AND SEX



Fig 4a. Bar chart, distribution of cases by age group and sex

Figures 4a shows that cancer cases in Mauritius for 2024 increase with age, peaking in the 60-64 age group for females and the 70-74 group for males. Older age groups have higher cases, especially among women, while younger age groups have significantly fewer cases.



Fig 4b. Pie chart, distribution of cases by age group and sex

Figures 4b shows that most cancer cases occur in the 50-69 age group, with 48.5% of cases in males and 48.0% in females. The 70+ group follows, with 38.0% of male cases and 29.4% of female cases. Cancer cases in younger age groups (0-14, 15-29, and 30-49) represent a significantly smaller proportion.

Overall, the data highlights a strong age-related pattern in cancer occurrence, with a heavier burden on older adults.

4.2 TRENDS OF THE NUMBER OF CASES BY 3- YEAR PERIOD



Fig 5. Average Number of cases by 3-year period

The total number of cancer cases has been steadily increasing over the years among both males and females. Overall, the number of cancer cases is higher among females than males for each period.

4.3 THE MOST COMMON CANCERS

In men, prostate is the most commonly diagnosed malignancy (n=251, 18.5%) cases, followed by colon, rectum, anus (n=209, 15.4%) and lungs (n= 137, 10.1%)).

In women, breast is the most commonly diagnosed malignancy (n= 679, 37.5%), followed by corpus uteri (n=191, 10.5%) and colon, rectum, anus (n= 177, 9.8%).



Fig 6a. Top 10 cancers, both sexes (Number of cases)



Fig 6b. Top 10 cancers, both sexes (Age-standardized rate per 100,000)

Figures 6a and 6b show the top 10 cancer sites among both sexes in number of cases and in ASR.

4.4 TOP 10 CANCERS, BY NUMBER OF CASES, PERCENTAGE, CRUDE INCIDENCE RATE AND BY AGE STANDARDIZED INCIDENCE RATE















Fig 7. Top 10 cancers, by number of cases, percentage, crude incidence rate and by age standardized incidence rate

Figure 7 illustrates the top 10 most common cancer sites among males and females in terms of number of cases, percentage, crude incidence rate and by age standardized incidence rate.

4.5 AGE-SPECIFIC INCIDENCE RATES (MOST COMMON SITES) BY SEX



Fig 8. Age-specific incidence rates

Figure 8 shows the age-specific cancer incidence rates for the top 5 cancer sites in both males and females. In males, prostate cancer has the highest incidence, rising sharply after age 50. Colon, rectum, lung, mouth, pharynx, and bladder cancers all increase with age, peaking in the 75-84 age group.

In females, breast cancer leads in incidence, particularly in those aged 50 and above, while uterine, colorectal, and ovarian cancers also rise steadily with age. Cervical cancer shows an earlier peak, likely due to screening and prevention efforts.

These trends highlight the increasing cancer risk with age, especially for prostate, colorectal, and lung cancers in males, and breast and uterine cancers in females.

4.6 Trends in Age Standardised Incidence Rate from 2001 to 2024, by gender and by the most common (top 5) cancer sites



Fig 9. Trends in Age Standardised Incidence Rate from 2001 to 2024 by gender

Figure 9 illustrates an upward trend in the overall ASR. The ASR for females consistently exceeds that of males, indicating higher cancer incidence among women for the different periods. Male incidence also increases overall, although with more variability, including a temporary decline in 2016–2018. Consequently, total incidence follows an upward trend, accelerating in the most recent periods.



Fig 10. Trends in Age Standardised Incidence Rate from 2001 to 2024 for the five most common sites among male

Trends in the age standardised incidence rates of prostate and colorectal cancers have increased over the last two decades. Lung and stomach cancers have remained stable while mouth and pharynx neoplasm has slightly decreased over time.



Fig 11. Trends in Age Standardised Incidence Rate from 2001 to 2024 for the five most common sites among female

Breast cancer is by far the most common cancer among women, with a significative increase of its ASR over time. Colorectal, together with corpus uteri and ovary trends have also increased significantly. Cervical cancer rates have decreased from 2001 to 2018 and have stabilised over the last few years.

4.7 COMPARISON OF SUMMARY RATES WITH OTHER REGIONAL COUNTRIES

Figure 12 shows a comparison of the age standardised incidence rates in the Mauritius National Cancer Registry (2024) with those observed in Reunion Island (2022), South Africa (2022) and Kenya (2022) and the World (GLOBOCAN, 2022). The top five most common cancer sites among males and females were compared with the regional countries having the closest socio-economic characteristics to Mauritius.















Fig 12. Comparison with other countries

4.8 BASIS OF DIAGNOSIS (DCO / CLINICAL / MV) BY SITE

Table 1 shows the percentage of cases at the major sites that were registered on the basis of information from a death certificate only (DCO) and with morphological verification (MV) - that is, based on cytology or histology (of the primary tumour, or a metastasis).

Most cancers have been diagnosed through Microscopic Verification. However, for certain tumor sites, such as the liver, pancreas, lung, ovary, and brain, where biopsies are more challenging, the percentage of Clinical diagnoses is higher. The percentage of DCO (Death Certificate Only) is 0%, as we only received anonymized death data from the Civil Status Office, making it impossible to determine when the cancer diagnosis was made relative to the time of death.

Data Quality Indicators

Cancer site	ICD-10	No. Cases	% total	Basis of diagnosis		
				% DCO	% Clinical	% M.V
Mouth & pharynx	C00-14	100	3.5	0.0	11.0	89.0
Oesophagus	C15	44	1.5	0.0	18.2	81.8
Stomach	C16	108	3.8	0.0	10.2	89.8
Colon, rectum, anus	C18-21	386	13.6	0.0	10.1	89.9
Liver	C22	63	2.2	0.0	23.8	76.2
Pancreas	C25	81	2.8	0.0	56.8	43.2
Larynx	C32	45	1.6	0.0	2.2	97.8
Trachea, bronchus, lung	C33-34	193	6.8	0.0	22.3	77.7
Melanoma of skin	C43	17	0.6	0.0	5.9	94.1
Breast	C50	687	24.1	0.0	9.8	90.2
Cervix	C53	85	3.0	0.0	16.5	83.5
Corpus & uterus NOS	C54-55	191	6.7	0.0	7.9	92.1
Ovary & adnexa	C56	108	3.8	0.0	43.5	56.5
Prostate	C61	251	8.8	0.0	11.6	88.4
Testis	C62	25	0.9	0.0	32.0	68.0
Kidney & urinary NOS	C64-66,68	59	2.1	0.0	15.3	84.7
Bladder	C67	88	3.1	0.0	13.6	86.4
Brain & central nervous system	C70-72	79	2.8	0.0	30.4	69.6
Thyroid	C73	39	1.4	0.0	5.1	94.9
Lymphoma	C81-85,90,88,96	127	4.5	0.0	2.4	97.6
Leukaemia	C91-95	70	2.5	0.0	0.0	100.0
All sites	All	2,846	100.0	0.0	14.2	85.8

Table 1.

4.9 CHILDHOOD CANCERS (0 TO 14 YEARS)

Table 2 shows incidence of childhood cancer, classified according to the International Classification of Childhood cancer (ICCC-3) (Steliarova-Foucher et al, 2005).

Childhood cancer (ages 0-14) is relatively rare compared to adult cancer. The most common types of cancer in children are leukaemia and CNS neoplasms.

ICCC3		Number of cases						Rates per million				
		0-4	5-9	10-14	All	M/F	% total	0-4	5-9	10-14	crude	ASR
	All	7	6	10	23	0.8	100.0	111.3	93.0	140.1	115.7	113.8
I	Leukaemias	3	3	0	6	0.2	26.1	47.7	46.5	0.0	30.2	33.5
II	Lymphomas	0	0	1	1	0.0	4.3	0.0	0.0	14.0	5.0	4.1
III	CNS neoplasms	0	0	3	3	2.0	13.0	0.0	0.0	42.0	15.1	12.2
IV	Neuroblastoma	1	0	1	2	1.0	8.7	15.9	0.0	14.0	10.1	10.2
V	Retinoblastoma	1	0	0	1	0.0	4.3	15.9	0.0	0.0	5.0	6.2
VI	Renal tumors	1	0	0	1	0.0	4.3	15.9	0.0	0.0	5.0	6.2
X	Germ cell tumors	0	1	0	1	0.0	4.3	0.0	15.5	0.0	5.0	5.0
XI-XII	Other	1	2	5	8	1.0	34.8	15.9	31.0	70.1	40.2	36.5

Table 2.

5 MORTALITY

This section on cancer mortality in the Republic of Mauritius represents all the cancer deaths registered for the year 2024.

After each calendar year, an anonymous listing of all death that occurred in the Republic of Mauritius from the Civil Status Office is transferred to the Statistical department of the Ministry of Health & Wellness. The causes of death are coded according to the ICD-10 classification before being handled to the National Cancer Registry. The data is further checked for misclassification of cancer cases and recoded whenever necessary. Hence, the mortality report included cancer patients who died from causes other than neoplasms; even if a patient died from a different condition rather than cancer itself, they were still included in the final mortality count.

Deaths due to benign neoplasms (except brain) are excluded from the study. Analysis of cancer data is then performed using STATA software and the results tabulated using EXCEL software.

Main conclusions of the cancer mortality study for 2024 are as follows:

1649 Deaths due to cancer have been registered during the year 2024, **803** in males and **846** in women. The Mortality/Incidence (MI) ratio is **0.55** for males and **0.45** for females.

Table 3 and 4 describe the most common cancer sites for mortality among both males and females in terms of number, percentage, crude rate and age standardised rate for the year 2024.

MOST COMMON SITES FOR MORTALITY CASES IN 2024 (MALE)

Site	Number	Percentage (%)	Crude Mortality Rate/10^5	ASR (World) /10^5
Trachea, Bronchus & Lung	123	15.3	20.0	12.0
Prostate	111	13.8	18.0	10.7
Colon, Rectum & Anus	102	12.7	16.5	10.2
Stomach	49	6.1	7.9	4.8
Pancreas	48	6.0	7.8	4.6
Mouth & Pharynx	43	5.4	7.0	4.3
Liver & Intra-hepatic bile ducts	40	5.0	6.5	4.1
Leukaemias	29	3.6	4.7	3.1
Oesophagus	28	3.5	4.5	2.7
Kidney, Pelvis& Ureter	27	3.4	4.4	2.8
Brain	27	3.4	4.4	2.8
Larynx	26	3.2	4.2	2.6
Others	150	18.6	24.4	15.7
Total	803	100.0	130.3	80.4

Table 3.

MOST COMMON SITES FOR MORTALITY CASES IN 2024 (FEMALE)

Site	Number	Percentage (%)	Crude Mortality Rate/10	ASR (World) /10^5
Breast	244	28.8	38.8	21.2
Colon, Rectum & Anus	96	11.3	15.3	7.2
Trachea, Bronchus & Lung	60	7.1	9.5	4.9
Ovary	60	7.1	9.5	5.6
Corpus Uteri	56	6.6	8.9	4.9
Cervix Uteri	47	5.6	7.5	4.6
Stomach	36	4.3	5.7	2.7
Mouth & Pharynx	29	3.4	4.6	2.3
Brain	27	3.2	4.3	2.5
Liver & Intra-hepatic bile ducts	24	2.8	3.8	1.8
Pancreas	22	2.6	3.5	1.9
Leukaemias	18	2.1	2.9	1.5
Others	116	13.7	18.5	10.5
Total	846	100.0	134.5	72.5

Table 4.

5.1 TOP 10 CANCERS, BY NUMBER OF CASES, PERCENTAGE, CRUDE INCIDENCE RATE AND BY AGE STANDARDIZED MORTALITY RATE















Fig 13. Top 10 cancers, by number of cases, percentage, crude mortality rate and by age standardized incidence rate

Figure 13 illustrates the top 10 most common cancer sites among males and females in terms of number of cases, percentage, crude mortality rate and by age standardized incidence rate. The three most common sites among males are: lungs, prostate and colon-rectum-anus, while among females, they are: breast, colon-rectum-anus and ovary.

5.2 Trends in Age Standardised Mortality Rate from 2014 to 2024, by gender and by the most common (top 5) cancer sites



Fig 13. Trends in Age Standardised Mortality Rate from 2014 to 2024 by gender

Figure 13 illustrates the trend in the Age Standardised Morality Rate (ASMR) by sex. The ASMR for males consistently exceeds that of females, indicating higher cancer mortality among male for the different periods. From 2014 to 2024, mortality among males shows an overall decline over time, despite a slight increase in the most recent period. In contrast, female mortality rises across the study period, reaching a peak in 2020–2022 before marginally decreasing thereafter. Owing to these opposing patterns, the total mortality rate remains largely stable, with only small variations across periods.



Fig 14. Trends in Age Standardised Mortality Rate from 2014 to 2024 for the five most common sites among male

The chart presents trends in Age Standardised Mortality Rates among males for the five most common cancers from 2014–2016 to 2023–2024. Lung cancer remains the leading cause of cancer mortality but shows a consistent decline over time. Prostate cancer mortality shows a slight increasing trend, while colorectal cancer mortality remains relatively stable with minor fluctuations. Stomach cancer declines after peaking in 2017–2019, and mouth and pharynx cancers have lower mortality rates that remain largely stable across the periods.



Fig 15. Trends in Age Standardised Mortality Rate from 2014 to 2024 for the five most common sites among male

The data indicate distinct temporal patterns in Age Standardised Mortality Rates for the five most common female cancers between 2014–2016 and 2023–2024. Breast cancer consistently exhibits the highest mortality rates and shows a gradual upward trend over time. Colorectal cancer mortality remains relatively stable, with modest fluctuations across periods. Lung and ovarian cancers show lower mortality rates overall and remain largely stable throughout the study period. In contrast, corpus uteri cancer exhibits a marked rise, particularly between 2020–2022 and 2023–2024.

5.3 COMPARISON OF SUMMARY RATES WITH OTHER REGIONAL COUNTRIES

Figure 16 shows a comparison of the Age Standardised Mortality Rates in the Mauritius National Cancer Registry (2024) with those observed in Reunion Island (2022), South Africa (2022) and Kenya (2022) and the World (GLOBOCAN, 2022). The top five most common cancer mortality sites among males and females were compared with the regional countries having the closest socio-economic characteristics to Mauritius.


Trachea, Bronchus, Lungs
Male
Reunion Island
World
South Africa
Mauritius NCR
Kenya
36.3
32.1
27.6
12.0
3.6
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0
Age Standardised Mortality Rate per 100,000


Breast
Female
Mauritius
Kenya
South Africa
World
Reunion Island
21.2
19.6
17.0
12.7
12.1
0.0 5.0 10.0 15.0 20.0 25.0
Age Standardised Mortality Rate per 100,000


Prostate
Male
South Africa
Kenya
Reunion Island
Mauritius NCR
World
30.7
24.4
12.2
10.7
7.3
0 5 10 15 20 25 30 35
Age Standardised Mortality Rate per 100,000


Colon Rectum
Female
Reunion Island
South Africa
Kenya
Mauritius NCR
World
8.0
7.6
7.3
7.2
6.5
0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0
Age Standardised Mortailty Rate per 100,000


Colon, Rectum, Anus
Male
South Africa
Reunion Island
Mauritius NCR
World
Kenya
10.8
10.6
10.2
9.9
9.0
0.0 2.0 4.0 6.0 8.0 10.0 12.0
Age Standardised Mortality Rate per 100,000


Ovary
Female
Kenya
Mauritius NCR
South Africa
World
Reunion Island
6.1
5.6
4.4
4.0
3.6
0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0
Age Standardised Mortality Rate per 100,000


Stomach
Male
Reunion Island
World
Kenya
Mauritius NCR
South Africa
8.9
8.6
6.4
4.8
4.1
0 2 4 6 8 10
Age Standardised Mortality Rate per 100,000


Trachea, Bronchus and Lungs
Female
South Africa
World
Reunion Island
Mauritius NCR
Kenya
10.5
9.8
7.5
4.9
3.0
0.0 2.0 4.0 6.0 8.0 10.0 12.0
Age Standardised Mortality Rate per 100,000


Pancreas
Male
Reunion Island
South Africa
World
Mauritius NCR
Kenya
7.5
5.3
5.0
4.6
3.7
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
Age Standardised Mortality Rate per 100,000


Corpus Uteri
Female
Mauritius NCR
South Africa
Kenya
World
Reunion Island
4.9
2.7
1.9
1.7
1.6
0
1
2
3
4
5
6
Age Standardised Mortality Rate per 100,000

6 APPENDIX

6.1 TABLES

6.1.1 Estimated mid-year population for Mauritius and Rodrigues 2024

Ages	Male	Female	World Population
0 - 4	31885	30993	: 12000
5 - 9	32966	31571	: 10000
10 - 14	36165	35189	: 9000
15 - 19	40991	40737	: 9000
20 - 24	43973	44755	: 8000
25 - 29	47349	44611	: 8000
30 - 34	51929	47655	: 6000
35 - 39	45695	41703	: 6000
40 - 44	47307	45349	: 6000
45 - 49	44376	44504	: 6000
50 - 54	38211	38561	: 5000
55 - 59	39971	41441	: 4000
60 - 64	38774	42030	: 4000
65 - 69	31042	35583	: 3000
70 - 74	23277	28788	: 2000
75 - 79	12624	17447	: 1000
80 - 84	5918	9588	: 500
85 +	4026	8465	: 500
Total	**616479**	**628970**	**: 100000**

6.1.2 Incident cases by age group in 2024 (Male)

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	(%)	ICD (10th)
Lip	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0.1	C00
Tongue	15	0	0	0	0	0	0	0	0	1	1	0	1	1	2	4	3	2	0	0	1.1	C01-02
Mouth	23	0	0	0	0	0	0	0	0	0	0	2	1	3	7	5	1	3	1	0	1.7	C03-06
Salivary glands	8	0	0	0	0	0	0	0	0	0	1	1	3	1	1	0	1	0	0	0	0.6	C07-08
Tonsil	8	0	0	0	0	0	0	0	0	0	0	1	1	0	4	2	0	0	0	0	0.6	C09
Other oropharynx	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0.1	C10
Nasopharynx	4	0	0	0	0	1	0	0	1	0	0	1	0	0	0	1	0	0	0	0	0.3	C11
Hypopharynx	6	0	0	0	0	0	0	0	0	0	0	2	1	0	1	2	0	0	0	0	0.4	C12-13
Pharynx unspecified	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0.1	C14
Oesophagus	30	0	0	0	0	0	0	0	0	0	0	1	1	5	8	4	6	4	0	1	2.2	C15
Stomach	66	0	0	0	0	0	0	1	1	0	2	3	5	7	13	10	11	4	5	4	4.9	C16
Small intestine	6	0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	1	2	0	0	0.4	C17
Colon	149	0	0	0	1	1	0	1	0	5	4	1	10	13	23	26	30	16	6	12	11	C18
Rectum	57	0	0	0	0	0	0	0	0	1	2	3	4	10	4	12	11	7	2	1	4.2	C19-20
Anus	3	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0.2	C21
Liver	47	0	0	0	0	0	0	0	0	0	0	3	4	6	8	9	9	4	3	1	3.5	C22
Gallbladder etc.	14	0	0	0	0	0	0	0	0	0	1	0	0	1	2	5	1	3	1	0	1	C23-24
Pancreas	53	0	0	1	0	0	0	0	0	0	1	2	5	9	6	13	9	5	1	1	3.9	C25
Nose, sinuses etc.	4	0	0	0	0	0	0	0	0	2	0	0	0	1	0	1	0	0	0	0	0.3	C30-31
Larynx	34	0	0	0	0	0	0	0	0	0	0	3	0	4	7	8	10	1	0	1	2.5	C32
Trachea, bronchus and lung	137	0	0	0	0	0	0	0	0	0	5	4	8	16	19	23	27	20	12	3	10.1	C33-34
Other thoracic organs	4	0	0	0	0	0	0	0	0	0	0	0	0	2	1	1	0	0	0	0	0.3	C37-38
Bone	4	0	0	0	0	0	1	1	0	0	1	0	0	0	1	0	0	0	0	0	0.3	C40-41
Melanoma of skin	6	0	0	0	0	0	0	0	0	0	0	0	0	3	1	1	0	1	0	0	0.4	C43
Other skin	115	0	0	0	0	0	0	0	1	0	7	4	16	10	20	16	10	15	9	7	8.5	C44
Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	C45
Kaposi sarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0.1	C46
Connective and soft tissue	11	0	0	1	0	2	0	0	0	1	1	1	1	0	0	0	2	1	0	1	0.8	C47,C49
Breast	8	0	0	0	0	0	1	0	0	0	1	2	0	0	2	1	1	0	0	0	0.6	C50
Penis	5	0	0	0	0	0	0	0	0	0	0	1	1	2	1	0	0	0	0	0	0.4	C60
Prostate	251	0	0	0	0	0	0	0	0	0	0	2	5	16	39	50	58	41	23	17	18.5	C61
Testis	25	0	0	0	0	7	2	2	8	1	2	0	0	1	1	1	0	0	0	0	1.8	C62
Other male genital organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.1	C63
Kidney	42	0	0	0	0	0	0	0	0	2	3	1	5	3	6	12	7	1	2	0	3.1	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	68	0	0	0	0	0	0	1	1	0	1	3	5	2	8	11	18	11	5	2	5	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	3	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0.2	C69
Brain, nervous system	42	0	1	0	2	1	0	1	1	3	1	3	6	8	4	3	5	2	1	0	3.1	C70-72
Thyroid	8	0	0	0	0	1	0	0	1	1	1	2	0	1	1	0	0	0	0	0	0.6	C73
Adrenal gland	2	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0.1	C74
Other endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C75
Hodgkin disease	8	0	0	0	0	0	1	0	3	1	0	1	0	0	0	1	0	0	0	1	0.6	C81
Non-Hodgkin lymphoma	39	0	0	0	1	0	4	0	2	0	1	3	4	5	8	3	6	2	0	0	2.9	C82-85,C96
Immunoproliferative diseases	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C88
Multiple myeloma	19	0	0	0	0	0	0	0	0	0	1	1	0	2	3	6	3	2	1	0	1.4	C90
Lymphoid leukaemia	10	0	0	1	0	1	0	0	0	1	0	0	1	1	0	1	1	2	0	1	0.7	C91
Myeloid leukaemia	24	0	0	0	0	0	2	0	1	0	1	2	0	3	3	2	3	2	4	1	1.8	C92-94
Leukaemia unspecified	8	0	0	0	0	0	1	0	0	0	1	0	1	0	0	1	3	0	1	0	0.6	C95
Myeloproliferative disorders	4	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	2	0	0	0.3	MPD
Myelodysplastic syndromes	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0.1	MDS
Other and unspecified	90	0	0	0	1	1	1	2	0	1	9	5	4	5	20	10	13	7	8	3	6.6	O&U
All sites	1471	0	2	3	5	15	13	10	20	21	49	61	93	144	227	249	253	161	87	58	108.5	ALL
All sites but C44	1356	0	2	3	5	15	13	10	19	21	42	57	77	134	207	233	243	146	78	51	100	ALLbC44

6.1.3 Incident cases by age group in 2024 (Female)

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	(%)	ICD (10th)
Lip	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0.1	C00
Tongue	11	0	0	0	0	0	1	0	2	0	1	0	1	1	3	1	0	0	1	0	0.6	C01-02
Mouth	5	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	1	0	0	0	0.3	C03-06
Salivary glands	6	0	0	0	0	0	0	0	0	1	0	0	0	0	1	2	1	0	1	0	0.3	C07-08
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	2	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0.1	C11
Hypopharynx	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	1	0.2	C12-13
Pharynx unspecified	2	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0.1	C14
Oesophagus	14	0	0	0	0	0	0	0	0	0	1	2	1	1	3	1	3	1	0	1	0.8	C15
Stomach	42	0	0	0	0	0	0	0	0	0	1	4	4	3	3	10	2	9	3	3	2.3	C16
Small intestine	7	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0	1	2	0	1	0.4	C17
Colon	124	0	0	0	0	2	0	1	0	1	2	4	8	16	24	17	17	17	9	6	6.9	C18
Rectum	53	0	0	0	0	0	0	0	0	2	3	3	6	6	6	6	7	6	5	3	2.9	C19-20
Anus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C21
Liver	16	0	0	0	0	0	0	0	2	0	0	1	1	1	0	2	7	2	0	0	0.9	C22
Gallbladder etc.	14	0	0	0	0	0	0	0	0	1	1	0	1	1	0	4	5	0	0	1	0.8	C23-24
Pancreas	28	0	0	0	0	0	0	1	0	0	3	1	3	1	6	6	4	3	0	0	1.5	C25
Nose, sinuses etc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C30-31
Larynx	11	0	0	0	0	0	0	0	0	0	0	0	0	1	5	3	1	0	0	1	0.6	C32
Trachea, bronchus and lung	57	0	0	0	0	0	0	1	1	0	0	3	2	10	11	5	12	7	2	3	3.1	C33-34
Other thoracic organs	5	0	0	0	1	0	0	0	0	0	0	0	0	2	1	0	1	0	0	0	0.3	C37-38
Bone	3	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	0	0	0.2	C40-41
Melanoma of skin	11	0	0	0	0	0	0	0	0	0	0	1	2	2	3	1	0	2	0	0	0.6	C43
Other skin	81	0	0	0	0	2	1	1	2	4	3	0	9	4	9	6	18	11	7	4	4.5	C44
Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.1	C45
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C46
Connective and soft tissue	9	0	0	0	0	0	0	1	0	1	0	0	2	0	1	2	0	1	1	0	0.5	C47,C49
Breast	679	0	0	0	0	0	1	11	17	17	52	65	66	85	95	85	76	59	28	22	37.5	C50
Vulva	4	0	0	0	0	0	0	0	0	0	0	0	0	0	3	0	0	0	1	0	0.2	C51
Vagina	3	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	1	0.2	C52
Cervix uteri	85	0	0	0	0	0	1	4	7	4	12	8	9	7	13	7	9	2	1	1	4.7	C53
Corpus uteri	171	0	0	0	0	1	0	0	5	6	5	11	21	28	24	36	26	4	4	0	9.4	C54
Uterus unspecified	20	0	0	0	0	0	0	0	1	0	2	4	2	2	0	3	4	0	1	1	1.1	C55
Ovary	108	0	0	1	0	1	0	2	4	13	6	4	6	10	18	10	17	7	6	3	6	C56
Other female genital organs	4	0	0	0	0	0	0	0	1	0	0	1	0	0	0	1	0	1	0	0	0.2	C57
Placenta	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	C58
Kidney	16	0	1	0	0	1	0	0	1	1	0	2	1	0	0	6	0	1	2	0	0.9	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.1	C66
Bladder	20	0	0	0	1	0	0	0	0	0	2	0	0	3	2	1	4	3	2	2	1.1	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.1	C69
Brain, nervous system	37	0	0	0	1	1	1	1	2	0	1	2	5	6	5	3	6	2	0	1	2	C70-72
Thyroid	31	0	0	0	0	1	3	0	2	5	2	3	2	3	5	1	4	0	0	0	1.7	C73
Adrenal gland	3	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0.2	C74
Other endocrine	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0.1	C75
Hodgkin disease	14	0	0	0	0	1	2	1	3	0	1	1	3	0	0	0	0	1	1	0	0.8	C81
Non-Hodgkin lymphoma	26	0	0	0	0	0	0	0	1	1	0	2	4	2	1	3	3	6	3	0	1.4	C82-85,C96
Immunoproliferative diseases	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.1	C88
Multiple myeloma	20	0	0	0	0	0	0	0	0	1	1	4	1	2	5	2	1	1	1	1	1.1	C90
Lymphoid leukaemia	10	0	2	2	0	1	0	0	0	0	0	0	0	2	1	0	0	0	1	1	0.6	C91
Myeloid leukaemia	15	0	1	0	0	0	1	1	0	0	0	0	0	1	1	2	4	2	2	0	0.8	C92-94
Leukaemia unspecified	3	0	0	0	0	1	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0.2	C95
Myeloproliferative disorders	3	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	1	0	0.2	MPD
Myelodysplastic syndromes	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0.1	MDS
Other and unspecified	105	0	1	0	2	1	0	2	1	3	6	10	11	11	15	16	11	12	2	1	5.8	O&U
All sites	1891	0	5	3	5	13	13	29	52	64	107	137	176	214	268	249	251	162	85	58	104.5	ALL
All sites but C44	1810	0	5	3	5	11	12	28	50	60	104	137	167	210	259	243	233	151	78	54	100	ALLbC44

6.1.4 Incidence by 100,000 by age group in 2024 (Male)

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	2	0	0	0	0	0	0	0	0	0	0	0	0	0	2.6	3.2	0	0	0	0	0.32	0.1	0.01	0.03	0.2	C00
Tongue	15	0	0	0	0	0	0	0	0	2.2	2.1	0	2.6	2.5	5.2	12.9	12.9	15.8	0	0	2.43	1.1	0.07	0.2	1.5	C01-02
Mouth	23	0	0	0	0	0	0	0	0	0	0	4.5	2.6	7.5	18.1	16.1	4.3	23.8	16.9	0	3.73	1.7	0.16	0.27	2.3	C03-06
Salivary glands	8	0	0	0	0	0	0	0	0	0	2.1	2.3	7.9	2.5	2.6	0	4.3	0	0	0	1.3	0.6	0.09	0.11	0.9	C07-08
Tonsil	8	0	0	0	0	0	0	0	0	0	0	2.3	2.6	0	10.3	6.4	0	0	0	0	1.3	0.6	0.08	0.11	0.9	C09
Other oropharynx	2	0	0	0	0	0	0	0	0	0	0	0	0	2.5	0	0	4.3	0	0	0	0.32	0.1	0.01	0.03	0.2	C10
Nasopharynx	4	0	0	0	0	2.4	0	0	1.9	0	0	2.3	0	0	0	3.2	0	0	0	0	0.65	0.3	0.03	0.05	0.6	C11
Hypopharynx	6	0	0	0	0	0	0	0	0	0	0	4.5	2.6	0	2.6	6.4	0	0	0	0	0.97	0.4	0.05	0.08	0.7	C12-13
Pharynx unspecified	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	16.9	0	0.16	0.1	0	0	0.1	C14
Oesophagus	30	0	0	0	0	0	0	0	0	0	0	2.3	2.6	12.5	20.6	12.9	25.8	31.7	0	24.8	4.87	2.2	0.19	0.38	2.9	C15
Stomach	66	0	0	0	0	0	0	2.1	1.9	0	4.2	6.8	13.1	17.5	33.5	32.2	47.3	31.7	84.5	99.4	10.71	4.9	0.4	0.79	6.8	C16
Small intestine	6	0	0	0	0	0	0	2.1	0	0	0	0	0	2.5	0	3.2	4.3	15.8	0	0	0.97	0.4	0.02	0.06	0.6	C17
Colon	149	0	0	0	2.8	2.4	0	2.1	0	10.9	8.5	2.3	26.2	32.5	59.3	83.8	128.9	126.7	101.4	298.1	24.17	11	0.73	1.8	15.3	C18
Rectum	57	0	0	0	0	0	0	0	0	2.2	4.2	6.8	10.5	25	10.3	38.7	47.3	55.4	33.8	24.8	9.25	4.2	0.29	0.72	5.7	C19-20
Anus	3	0	0	0	0	0	0	0	0	0	0	2.3	0	0	0	3.2	4.3	0	0	0	0.49	0.2	0.01	0.05	0.3	C21
Liver	47	0	0	0	0	0	0	0	0	0	0	6.8	10.5	15	20.6	29	38.7	31.7	50.7	24.8	7.62	3.5	0.26	0.6	4.7	C22
Gallbladder etc.	14	0	0	0	0	0	0	0	0	0	2.1	0	0	2.5	5.2	16.1	4.3	23.8	16.9	0	2.27	1	0.05	0.15	1.3	C23-24
Pancreas	53	0	0	3	0	0	0	0	0	0	2.1	4.5	13.1	22.5	15.5	41.9	38.7	39.6	16.9	24.8	8.6	3.9	0.3	0.71	5.5	C25
Nose, sinuses etc.	4	0	0	0	0	0	0	0	0	4.4	0	0	0	2.5	0	3.2	0	0	0	0	0.65	0.3	0.03	0.05	0.5	C30-31
Larynx	34	0	0	0	0	0	0	0	0	0	0	6.8	0	10	18.1	25.8	43	7.9	0	24.8	5.52	2.5	0.17	0.52	3.4	C32
Trachea, bronchus and lung	137	0	0	0	0	0	0	0	0	0	10.6	9	20.9	40	49	74.1	116	158.4	202.8	74.5	22.22	10.1	0.65	1.6	13.3	C33-34
Other thoracic organs	4	0	0	0	0	0	0	0	0	0	0	0	0	5	2.6	3.2	0	0	0	0	0.65	0.3	0.04	0.05	0.4	C37-38
Bone	4	0	0	0	0	0	2.3	2.1	0	0	2.1	0	0	0	2.6	0	0	0	0	0	0.65	0.3	0.05	0.05	0.6	C40-41
Melanoma of skin	6	0	0	0	0	0	0	0	0	0	0	0	0	7.5	2.6	3.2	0	7.9	0	0	0.97	0.4	0.05	0.07	0.6	C43
Other skin	115	0	0	0	0	0	0	0	1.9	0	14.8	9	41.9	25	51.6	51.5	43	118.8	152.1	173.9	18.65	8.5	0.72	1.19	11.9	C44
Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2.6	0	0	0	0	0	0.16	0.1	0.01	0.01	0.1	C45
Kaposi sarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0	2.5	0	3.2	0	0	0	0	0.32	0.1	0.01	0.03	0.2	C46
Connective and soft tissue	11	0	0	3	0	4.9	0	0	0	2.2	2.1	2.3	2.6	0	0	0	8.6	7.9	0	24.8	1.78	0.8	0.09	0.13	1.6	C47,C49
Breast	8	0	0	0	0	0	2.3	0	0	0	2.1	4.5	0	0	5.2	3.2	4.3	0	0	0	1.3	0.6	0.07	0.11	1	C50
Penis	5	0	0	0	0	0	0	0	0	0	0	2.3	2.6	5	2.6	0	0	0	0	0	0.81	0.4	0.06	0.06	0.6	C60
Prostate	251	0	0	0	0	0	0	0	0	0	0	4.5	13.1	40	100.6	161.1	249.2	324.8	388.6	422.3	40.72	18.5	0.79	2.84	23.7	C61
Testis	25	0	0	0	0	17.1	4.5	4.2	15.4	2.2	4.2	0	0	2.5	2.6	3.2	0	0	0	0	4.06	1.8	0.26	0.28	3.8	C62
Other male genital organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	24.8	0.16	0.1	0	0	0.1	C63
Kidney	42	0	0	0	0	0	0	0	0	4.4	6.3	2.3	13.1	7.5	15.5	38.7	30.1	7.9	33.8	0	6.81	3.1	0.25	0.59	4.4	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	68	0	0	0	0	0	0	2.1	1.9	0	2.1	6.8	13.1	5	20.6	35.4	77.3	87.1	84.5	49.7	11.03	5	0.26	0.82	6.6	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	3	0	3.1	0	0	0	0	0	0	2.2	0	0	0	0	0	0	4.3	0	0	0	0.49	0.2	0.03	0.05	0.6	C69
Brain, nervous system	42	0	3.1	0	5.5	2.4	0	2.1	1.9	6.6	2.1	6.8	15.7	20	10.3	9.7	21.5	15.8	16.9	0	6.81	3.1	0.38	0.54	5.3	C70-72
Thyroid	8	0	0	0	0	2.4	0	0	1.9	2.2	2.1	4.5	0	2.5	2.6	0	0	0	0	0	1.3	0.6	0.09	0.09	1.1	C73
Adrenal gland	2	0	0	0	0	0	0	0	0	0	2.1	2.3	0	0	0	0	0	0	0	0	0.32	0.1	0.02	0.02	0.3	C74
Other endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C75
Hodgkin disease	8	0	0	0	0	0	2.3	0	5.8	2.2	0	2.3	0	0	0	3.2	0	0	0	24.8	1.3	0.6	0.06	0.08	1	C81
Non-Hodgkin lymphoma	39	0	0	0	2.8	0	9.1	0	3.9	0	2.1	6.8	10.5	12.5	20.6	9.7	25.8	15.8	0	0	6.33	2.9	0.34	0.52	4.6	C82-85,C96
Immunoproliferative diseases	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C88
Multiple myeloma	19	0	0	0	0	0	0	0	0	0	2.1	2.3	0	5	7.7	19.3	12.9	15.8	16.9	0	3.08	1.4	0.09	0.25	1.9	C90
Lymphoid leukaemia	10	0	0	3	0	2.4	0	0	0	2.2	0	0	2.6	2.5	0	3.2	4.3	15.8	0	24.8	1.62	0.7	0.06	0.1	1.4	C91
Myeloid leukaemia	24	0	0	0	0	0	4.5	0	1.9	0	2.1	4.5	0	7.5	7.7	6.4	12.9	15.8	67.6	24.8	3.89	1.8	0.14	0.24	2.6	C92-94
Leukaemia unspecified	8	0	0	0	0	0	2.3	0	0	0	2.1	0	2.6	0	0	3.2	12.9	0	16.9	0	1.3	0.6	0.04	0.12	0.9	C95
Myeloproliferative disorders	4	0	0	0	0	0	0	0	0	0	0	2.3	0	0	2.6	0	0	15.8	0	0	0.65	0.3	0.02	0.02	0.4	MPD
Myelodysplastic syndromes	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7.9	16.9	0	0.32	0.1	0	0	0.2	MDS
Other and unspecified	90	0	0	0	2.8	2.4	2.3	4.2	0	2.2	19	11.3	10.5	12.5	51.6	32.2	55.8	55.4	135.2	74.5	14.6	6.6	0.59	1.03	9.7	O&U
All sites	1471	0	6.3	9.1	13.8	36.6	29.6	21.1	38.5	46	103.6	137.5	243.4	360.3	585.4	802.1	1086.9	1275.3	1470.1	1440.6	238.61	108.5	8.16	17.6	152.9	ALL
All sites but C44	1356	0	6.3	9.1	13.8	36.6	29.6	21.1	36.6	46	88.8	128.4	201.5	335.2	533.9	750.6	1043.9	1156.5	1318	1266.8	219.96	100	7.43	16.41	141	ALLbC44

6.1.5 Incidence by 100,000 by age group in 2024 (Female)

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2.8	3.5	0	0	0	0.32	0.1	0	0.03	0.2	C00
Tongue	11	0	0	0	0	0	2.2	0	4.2	0	2.2	0	2.6	2.4	7.1	2.8	0	0	10.4	0	1.75	0.6	0.1	0.12	1.2	C01-02
Mouth	5	0	0	0	0	0	0	0	0	0	0	0	0	2.4	2.4	5.6	3.5	0	0	0	0.79	0.3	0.02	0.07	0.4	C03-06
Salivary glands	6	0	0	0	0	0	0	0	0	2.4	0	0	0	0	2.4	5.6	3.5	0	10.4	0	0.95	0.3	0.02	0.07	0.5	C07-08
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C10
Nasopharynx	2	0	0	0	0	0	2.2	0	0	0	0	2.2	0	0	0	0	0	0	0	0	0.32	0.1	0.02	0.02	0.3	C11
Hypopharynx	3	0	0	0	0	0	0	0	0	0	0	0	0	2.4	0	2.8	0	0	0	11.8	0.48	0.2	0.01	0.03	0.2	C12-13
Pharynx unspecified	2	0	0	0	0	0	0	0	0	2.4	0	0	0	0	2.4	0	0	0	0	0	0.32	0.1	0.02	0.02	0.2	C14
Oesophagus	14	0	0	0	0	0	0	0	0	0	2.2	4.5	2.6	2.4	7.1	2.8	10.4	5.7	0	11.8	2.23	0.8	0.09	0.16	1.3	C15
Stomach	42	0	0	0	0	0	0	0	0	0	2.2	9	10.4	7.2	7.1	28.1	6.9	51.6	31.3	35.4	6.68	2.3	0.18	0.35	3.6	C16
Small intestine	7	0	0	0	0	0	0	0	0	0	0	0	5.2	0	2.4	0	3.5	11.5	0	11.8	1.11	0.4	0.04	0.06	0.6	C17
Colon	124	0	0	0	0	4.9	0	2.2	0	2.4	4.4	9	20.7	38.6	57.1	47.8	59.1	97.4	93.9	70.9	19.71	6.9	0.7	1.23	10.8	C18
Rectum	53	0	0	0	0	0	0	0	0	4.8	6.6	6.7	15.6	14.5	14.3	16.9	24.3	34.4	52.1	35.4	8.43	2.9	0.31	0.52	4.8	C19-20
Anus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C21
Liver	16	0	0	0	0	0	0	0	4.2	0	0	2.2	2.6	2.4	0	5.6	24.3	11.5	0	0	2.54	0.9	0.06	0.21	1.4	C22
Gallbladder etc.	14	0	0	0	0	0	0	0	0	2.4	2.2	0	2.6	2.4	0	11.2	17.4	0	0	11.8	2.23	0.8	0.05	0.19	1.2	C23-24
Pancreas	28	0	0	0	0	0	0	2.2	0	0	6.6	2.2	7.8	2.4	14.3	16.9	13.9	17.2	0	0	4.45	1.5	0.18	0.33	2.7	C25
Nose, sinuses etc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C30-31
Larynx	11	0	0	0	0	0	0	0	0	0	0	0	0	2.4	11.9	8.4	3.5	0	0	11.8	1.75	0.6	0.07	0.13	1	C32
Trachea, bronchus and lung	57	0	0	0	0	0	0	2.2	2.1	0	0	6.7	5.2	24.1	26.2	14.1	41.7	40.1	20.9	35.4	9.06	3.1	0.33	0.61	4.9	C33-34
Other thoracic organs	5	0	0	0	2.8	0	0	0	0	0	0	0	0	4.8	2.4	0	3.5	0	0	0	0.79	0.3	0.05	0.07	0.6	C37-38
Bone	3	0	0	0	0	0	0	0	0	2.4	0	0	0	0	2.4	0	3.5	0	0	0	0.48	0.2	0.02	0.04	0.3	C40-41
Melanoma of skin	11	0	0	0	0	0	0	0	0	0	0	2.2	5.2	4.8	7.1	2.8	0	11.5	0	0	1.75	0.6	0.1	0.11	1.1	C43
Other skin	81	0	0	0	0	4.9	2.2	2.2	4.2	9.6	6.6	0	23.3	9.7	21.4	16.9	62.5	63	73	47.3	12.88	4.5	0.42	0.82	7.4	C44
Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3.5	0	0	0	0.16	0.1	0	0.02	0.1	C45
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C46
Connective and soft tissue	9	0	0	0	0	0	0	2.2	0	2.4	0	0	5.2	0	2.4	5.6	0	5.7	10.4	0	1.43	0.5	0.06	0.09	1	C47,C49
Breast	679	0	0	0	0	0	2.2	24.7	35.7	40.8	114.7	146.1	171.2	205.1	226	238.9	264	338.2	292	259.9	107.95	37.5	4.83	7.35	66.8	C50
Vulva	4	0	0	0	0	0	0	0	0	0	0	0	0	0	7.1	0	0	0	10.4	0	0.64	0.2	0.04	0.04	0.3	C51
Vagina	3	0	0	0	0	0	0	0	0	0	2.2	0	0	0	0	2.8	0	0	0	11.8	0.48	0.2	0.01	0.03	0.3	C52
Cervix uteri	85	0	0	0	0	0	2.2	9	14.7	9.6	26.5	18	23.3	16.9	30.9	19.7	31.3	11.5	10.4	11.8	13.51	4.7	0.76	1.01	9.5	C53
Corpus uteri	171	0	0	0	0	2.5	0	0	10.5	14.4	11	24.7	54.5	67.6	57.1	101.2	90.3	22.9	41.7	0	27.19	9.4	1.21	2.17	16.8	C54
Uterus unspecified	20	0	0	0	0	0	0	0	2.1	0	4.4	9	5.2	4.8	0	8.4	13.9	0	10.4	11.8	3.18	1.1	0.13	0.24	2	C55
Ovary	108	0	0	3.2	0	2.5	0	4.5	8.4	31.2	13.2	9	15.6	24.1	42.8	28.1	59.1	40.1	62.6	35.4	17.17	6	0.77	1.21	11	C56
Other female genital organs	4	0	0	0	0	0	0	0	2.1	0	0	2.2	0	0	0	2.8	0	5.7	0	0	0.64	0.2	0.02	0.04	0.4	C57
Placenta	1	0	0	0	0	0	2.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0.16	0.1	0.01	0.01	0.2	C58
Kidney	16	0	3.2	0	0	2.5	0	0	2.1	2.4	0	4.5	2.6	0	0	16.9	0	5.7	20.9	0	2.54	0.9	0.09	0.17	1.9	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	1	0	0	0	0	0	0	0	0	0	2.2	0	0	0	0	0	0	0	0	0	0.16	0.1	0.01	0.01	0.1	C66
Bladder	20	0	0	0	2.8	0	0	0	0	0	4.4	0	0	7.2	4.8	2.8	13.9	17.2	20.9	23.6	3.18	1.1	0.1	0.18	1.8	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	1	0	0	0	0	0	0	0	0	0	0	0	0	2.4	0	0	0	0	0	0	0.16	0.1	0.01	0.01	0.1	C69
Brain, nervous system	37	0	0	0	2.8	2.5	2.2	2.2	4.2	0	2.2	4.5	13	14.5	11.9	8.4	20.8	11.5	0	11.8	5.88	2	0.3	0.45	4	C70-72
Thyroid	31	0	0	0	0	2.5	6.7	0	4.2	12	4.4	6.7	5.2	7.2	11.9	2.8	13.9	0	0	0	4.93	1.7	0.3	0.39	3.8	C73
Adrenal gland	3	0	0	0	0	0	0	0	0	0	0	0	2.6	0	0	2.8	3.5	0	0	0	0.48	0.2	0.01	0.04	0.3	C74
Other endocrine	1	0	0	0	0	0	0	2.2	0	0	0	0	0	0	0	0	0	0	0	0	0.16	0.1	0.01	0.01	0.2	C75
Hodgkin disease	14	0	0	0	0	2.5	4.5	2.2	6.3	0	2.2	2.2	7.8	0	0	0	0	5.7	10.4	0	2.23	0.8	0.14	0.14	1.9	C81
Non-Hodgkin lymphoma	26	0	0	0	0	0	0	0	2.1	2.4	0	4.5	10.4	4.8	2.4	8.4	10.4	34.4	31.3	0	4.13	1.4	0.13	0.23	2.3	C82-85,C96
Immunoproliferative diseases	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3.5	0	0	0	0.16	0.1	0	0.02	0.1	C88
Multiple myeloma	20	0	0	0	0	0	0	0	0	2.4	2.2	9	2.6	4.8	11.9	5.6	3.5	5.7	10.4	11.8	3.18	1.1	0.16	0.21	2	C90
Lymphoid leukaemia	10	0	6.5	6.3	0	2.5	0	0	0	0	0	0	0	4.8	2.4	0	0	0	10.4	11.8	1.59	0.6	0.11	0.11	2	C91
Myeloid leukaemia	15	0	3.2	0	0	0	2.2	2.2	0	0	0	0	0	2.4	2.4	5.6	13.9	11.5	20.9	0	2.38	0.8	0.06	0.16	1.6	C92-94
Leukaemia unspecified	3	0	0	0	0	2.5	0	2.2	0	0	0	0	2.6	0	0	0	0	0	0	0	0.48	0.2	0.04	0.04	0.5	C95
Myeloproliferative disorders	3	0	0	0	0	0	0	0	0	2.4	0	0	2.6	0	0	0	0	0	10.4	0	0.48	0.2	0.02	0.02	0.3	MPD
Myelodysplastic syndromes	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2.8	3.5	0	0	0	0.32	0.1	0	0.03	0.2	MDS
Other and unspecified	105	0	3.2	0	5.7	2.5	0	4.5	2.1	7.2	13.2	22.5	28.5	26.5	35.7	45	38.2	68.8	20.9	11.8	16.69	5.8	0.76	1.17	11.1	O&U
All sites	1891	0	16.1	9.5	14.2	31.9	29	65	109.1	153.5	235.9	307.8	456.4	516.4	637.6	699.8	871.9	928.5	886.5	685.2	300.65	104.5	12.91	20.77	187.5	ALL
All sites but C44	1810	0	16.1	9.5	14.2	27	26.8	62.8	104.9	143.9	229.3	307.8	433.1	506.7	616.2	682.9	809.4	865.5	813.5	637.9	287.77	100	12.49	19.95	180.1	ALLbC44

6.1.6 Cancer deaths by site and age group in 2024 (Male)

ICD CODE	SITE OF TUMOURS	0-4 yrs	5-9 yrs	10-14 yrs	15-19 yrs	20-24 yrs	25-29 yrs	30-34 yrs	35-39 yrs	40-44 yrs	45-49 yrs	50-54 yrs	55-59 yrs	60-64 yrs	65-69 yrs	70-74 yrs	75-79 yrs	80-84 yrs	85+	TOTAL	SEX Ratio
C00-C99	**All sites**	**0**	**0**	**0**	**1**	**6**	**6**	**7**	**11**	**16**	**28**	**40**	**70**	**104**	**135**	**146**	**98**	**77**	**58**	**803**	**0.95**
C00-C14	**Mouth & Pharynx**									**3**	**3**	**1**	**6**	**10**	**5**	**8**	**3**	**3**	**1**	**43**	**1.5**
C00	Lip																1			1	1.0
C01,C02	Tongue									2			2	3	2	2		1		12	1.3
C03	Gum																			0	0.0
C04	Floor of mouth																			0	0.0
C05,C06	Palate and other parts of mouth										1	1	2	2		2	2			10	1.4
C07,C08	Parotid and Major Salivary Glands													1	1					2	1.0
C09	Tonsil										1			1	1					3	
C10	Oropharynx															2				2	
C11	Nasopharynx									1				2						3	
C12,C13	Pyriform sinus & Hypopharynx												1			1				2	0.5
C14	Ill-defined sites LOP										1		1	1	1	1		2	1	8	2.0
C15-C26	**Digestive Organs**						**1**	**2**	**3**	**3**	**14**	**13**	**28**	**33**	**61**	**51**	**31**	**22**	**17**	**279**	**1.4**
C15	Oesophagus										2	1	4	4	4	6	4	2	1	28	4.0
C16	Stomach							1		1	2	3	2	8	10	10	5	5	2	49	1.4
C17	Small Intestine												2						1	3	0.5
C18-C20	Colorectal							1	3	2	4	5	11	9	20	17	13	9	8	102	1.1
C21	Anus & anal canal														1					1	1.0

Cancer deaths by site and age group in 2024 (Male)

ICD CODE	SITE OF TUMOUR	0-4 yrs	5-9 yrs	10-14 yrs	15-19 yrs	20-24 yrs	25-29 yrs	30-34 yrs	35-39 yrs	40-44 yrs	45-49 yrs	50-54 yrs	55-59 yrs	60-64 yrs	65-69 yrs	70-74 yrs	75-79 yrs	80-84 yrs	85+	TOTAL	SEX Ratio
C22	Liver & Intra-hepatic bile ducts						1				4	2	5	5	10	5	3	3	2	40	1.7
C23-C24	Gall Bladder and other parts of biliary tract											1	0	1	1	1	2	1	0	7	0.6
C25	Pancreas										2	1	4	6	15	12	4	2	2	48	2.2
C26	Ill-defined Digestive Organs																		1	1	0.5
C30-C39	**Resp. System & Intra-thoracic Organs**								**1**	**2**	**4**	**12**	**15**	**23**	**20**	**34**	**16**	**17**	**7**	**151**	**2.3**
C30,C31	Nasal cavity & accessory sinuses																			0	
C32	Larynx										2	1	6	4	2	6	3	1	1	26	5.2
C33-C34	Trachea, Bronchus& Lung									2	2	11	9	19	18	28	12	16	6	123	2.1
C37-C39	Thymus, Heart, mediastinum & pleura, Ill-defined sites resp. system								1								1			2	2.0
C40-C41	Bones & Articular Cartilage							1		1				1		1	1			5	2.5
C43- C44	Melanoma & other Skin													1	1	1	1	1		5	1.0
C45-C49	Mesothelial, Conn. & Soft tissue								1	1	1	1	1	3	1	3	1		1	14	2.8
C50	Breast															1				1	0.0
C60-C63	**Male Genital Organs**					**2**	**1**	**1**	**1**	**2**	**2**	**1**	**7**	**4**	**18**	**13**	**23**	**25**	**22**	**122**	
C60,C63	Penis & other MGOs									1			3				1			5	
C61	Prostate								1		1	1	4	4	18	13	22	25	22	111	
C62	Testis					2	1	1		1	1									6	

Cancer deaths by site and age group in 2024 (Male)

ICD CODE	SITE OF TUMOUR	0-4 yrs	5-9 yrs	10-14 yrs	15-19 yrs	20-24 yrs	25-29 yrs	30-34 yrs	35-39 yrs	40-44 yrs	45-49 yrs	50-54 yrs	55-59 yrs	60-64 yrs	65-69 yrs	70-74 yrs	75-79 yrs	80-84 yrs	85+	TOTAL	SEX Ratio
C64-C68	**Urinary Tract**						**1**		**1**	**1**		**3**	**3**	**7**	**10**	**15**	**4**	**3**	**5**	**53**	**5.3**
C67	Bladder								1			1	1	3	5	5	4	3	3	26	8.7
C64-66,C68	Kidney, Pelvis& Ureter						1			1		2	2	4	5	10			2	27	3.9
C69-C72	**Eye, Brain & other C.N.S**					**1**	**1**	**2**				**3**	**5**	**5**	**2**	**4**	**4**	**1**		**28**	**1.0**
C69	Eye & adnexa																			0	
C71	Brain					1	1	2				3	5	5	2	3	4	1		27	1.0
C70,C72	Meninges, Spinal Cord& other CNS															1				1	
C73-C75	**Thyroid & other Endocrine Glands**														**2**		**1**	**1**		**4**	**0.6**
C73	Thyroid Gland														1		1			2	0.5
C74-C75	Other Endocrine Glands														1			1		2	0.7
C76-C80	**Primary Site Unknown**						**1**			**1**	**3**	**2**	**3**	**11**	**8**	**8**	**6**		**3**	**46**	**1.3**
C81-C96	**Haematological Malignancies**				**1**	**3**	**1**	**1**	**4**	**2**	**1**	**4**	**2**	**6**	**7**	**7**	**7**	**4**	**2**	**52**	1.3
C81	Hodgkin's Disease						1													1	0.5
C82-86,C96	NHML					2			3			2	1	4	3	1	3			19	1.9
C88,C90	Multiple Myeloma												1			1	1			3	0.3
C91-95	Leukaemias				1	1		1	1	2	1	2		2	4	5	3	4	2	29	1.6
ALL SITES	**TOTAL**	**0**	**0**	**0**	**1**	**6**	**6**	**7**	**11**	**16**	**28**	**40**	**70**	**104**	**135**	**146**	**98**	**77**	**58**	**803**	**0.95**

6.1.7 Cancer deaths by site and age group in 2024 (Female)

ICD CODE	SITE OF TUMOURS	0-4 yrs	5-9 yrs	10-14 yrs	15-19 yrs	20-24 yrs	25-29 yrs	30-34 yrs	35-39 yrs	40-44 yrs	45-49 yrs	50-54 yrs	55-59 yrs	60-64 yrs	65-69 yrs	70-74 yrs	75-79 yrs	80-84 yrs	85+	TOTAL	SEX Ratio
C00-C99	**All sites**	**1**	**0**	**0**	**2**	**1**	**3**	**7**	**15**	**19**	**41**	**55**	**89**	**116**	**107**	**158**	**86**	**70**	**76**	**846**	**0.95**
C00-C14	**Mouth & Pharynx**									**1**		**1**	**4**	**4**	**4**	**6**	**2**	**1**	**6**	**29**	**1.5**
C00	Lip															1				1	1.0
C01,C02	Tongue													2	2	2	1	1	1	9	1.3
C03	Gum																		1	1	0.0
C04	Floor of mouth												1							1	0.0
C05,C06	Palate and other parts of mouth											1		1	1	1	1		2	7	1.4
C07,C08	Parotid and Major Salivary Glands															1			1	2	1.0
C09	Tonsil																			0	
C10	Oropharynx																			0	
C11	Nasopharynx																			0	
C12,C13	Pyriform sinus & Hypopharynx									1			2			1				4	0.5
C14	Ill-defined sites LOP												1	1	1				1	4	2.0
C15-C26	**Digestive Organs**							**1**		**3**	**8**	**8**	**13**	**32**	**21**	**41**	**28**	**24**	**26**	**205**	**1.4**
C15	Oesophagus										3			3	1					7	4.0
C16	Stomach										1	1	3	7	3	4	6	6	5	36	1.4
C17	Small Intestine									1					1	1	2		1	6	0.5
C18-C20	Colorectal							1		1	3	2	9	11	7	22	15	12	13	96	1.1
C21	Anus & anal canal																1			1	1.0
C22	Liver & Intra-hepatic bile ducts										1	2	1	1	2	7	2	2	6	24	1.7

Cancer deaths by site and age group in 2024 (Female)

ICD CODE	SITE OF TUMOURS	0-4 yrs	5-9 yrs	10-14 yrs	15-19 yrs	20-24 yrs	25-29 yrs	30-34 yrs	35-39 yrs	40-44 yrs	45-49 yrs	50-54 yrs	55-59 yrs	60-64 yrs	65-69 yrs	70-74 yrs	75-79 yrs	80-84 yrs	85+	TOTAL	SEX Ratio
C23-C24	Gall Bladder													5		4		2		11	0.6
C25	Pancreas									1		3		4	7	3	2	1	1	22	2.2
C26	Ill-defined Digestive Orgs													1				1		2	0.5
C30-C39	**Resp. System & Intrathoracic Organs**								**2**		**3**	**4**	**4**	**8**	**16**	**14**	**7**	**1**	**7**	**66**	**2.3**
C30,C31	Nasal cavity & accessory organs																			0	
C32	Larynx											2	1	1	1					5	5.2
C33-C34	Trachea, Bronchus& Lung								2		3	2	3	7	15	13	7	1	7	60	2.1
C37-C39	Thymus, Heart, mediastinum & pleura, Ill-def site resp sys															1				1	2.0
C40-C41	Bones & Articular Cartilage				1	1														2	2.5
C43-C44	Melanoma & other Skin								1							1	1	1	1	5	1.0
C45-C49	Mesothelial, Conn. & Soft Tissue												1	1		3				5	2.8
C50	**Breast**						1	2	4	3	19	17	34	29	30	46	21	21	17	244	0.0
C51-C58	**Female Genital Organs**							**4**	**6**	**9**	**7**	**18**	**20**	**24**	**17**	**27**	**14**	**13**	**11**	**170**	
C51-C52	Vulva,Vagina															2	1	2		5	
C53	Cervix Uteri							1	4	5	2	5	8	3	3	6	4	3	3	47	
C54-C55	Corpus Uteri									2	3	5	5	8	11	11	5	4	2	56	
C56	Ovary							3	2	2	2	8	7	12	3	8	3	4	6	60	

Cancer deaths by site and age group in 2024 (Female)

ICD CODE	SITE OF TUMOURS	0-4 yrs	5-9 yrs	10-14 yrs	15-19 yrs	20-24 yrs	25-29 yrs	30-34 yrs	35-39 yrs	40-44 yrs	45-49 yrs	50-54 yrs	55-59 yrs	60-64 yrs	65-69 yrs	70-74 yrs	75-79 yrs	80-84 yrs	85+	TOTAL	SEX Ratio
C57-C58	OAU Female Genital Organs													1			1			2	
C64-C68	**Urinary Tract**	**1**											**1**	**1**	**3**	**1**		**1**	**2**	**10**	**5.3**
C67	Bladder												1			1			1	3	8.7
C64-66,C68	Kidney, Pelvis& Ureter	1												1	3			1	1	7	3.9
C69-C72	**Eye, Brain & other C.N.S**				**1**				**1**	**1**	**1**	**3**	**1**	**2**	**5**	**5**	**4**	**2**	**1**	**27**	**1.0**
C69	Eye & adnexa																			0	
C71	Brain				1				1	1	1	3	1	2	5	5	4	2	1	27	1.0
C70,C72	Meninges, Spinal Cord & other CNS																			0	
C73-C75	**Thyroid & other Endocrine Glands**											**1**	**2**	**2**	**1**			**1**		**7**	**0.6**
C73	Thyroid Gland												1	1	1			1		4	0.5
C74-C75	Other Endocrine Glands											1	1	1						3	0.7
C76-C80	**Primary Site Uncertain**						**2**		**1**		**1**	**1**	**4**	**8**	**5**	**7**	**3**	**1**	**2**	**35**	**1.3**
C81-C96	**Haematological Malignancies**									**2**	**2**	**2**	**5**	**5**	**5**	**7**	**6**	**4**	**3**	**41**	**1.3**
C81	Hodgkin's Disease									1						1				2	0.5
C82-86,C96	NHML										1	1			1	2	3	2		10	1.9
C88,C90	Multiple Myeloma										1		1	4	2	1		1	1	11	0.3
C91-95	Leukaemias									1		1	4	1	2	3	3	1	2	18	1.6
All Site	**TOTAL**	**1**	**0**	**0**	**2**	**1**	**3**	**7**	**15**	**19**	**41**	**55**	**89**	**116**	**107**	**158**	**86**	**70**	**76**	**846**	**0.95**